A biosimilar is a biological drug that is similar to an approved biological drug and has no clinically significant differences in efficacy and safety. Biological drugs are complex compounds grown in or derived from living cell lines. Our expanding biosimilars portfolio focuses on inflammatory and immune diseases and oncology.
Within these therapeutic areas, we have several candidates at various stages of development, reinforcing our commitment to continuous innovation in biological therapies. We are committed to providing more patients with access to affordable alternative treatment options and helping to reduce the cost burden on healthcare systems.
By entering the Healthcare Professional Area you are confirming you are a GB Healthcare Professional. This area contains promotional information. If you are not a Healthcare Professional you will be directed to the Fresenius Kabi GB Corporate website.
